Citadel Advisors’s Icosavax, Inc. Common Stock ICVX Stock Holding History

Citadel Advisors’s Portfolio ICVX Stock Details ICVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-7,300	Closed	-$115K	–	15791
2023 Q4	$115K	Sell	7,300 -700	-9%	-$6.74K	﹤0.01%	10755
2023 Q3	$62K	Buy	8,000 +2,300	+40%	+$19.1K	﹤0.01%	11488
2023 Q2	$56.6K	Sell	5,700 -7,000	-55%	-$56K	﹤0.01%	11659
2023 Q1	$73.7K	Sell	12,700 -21,900	-63%	-$189K	﹤0.01%	11664
2022 Q4	$275K	Buy	34,600 +19,400	+128%	+$83.3K	﹤0.01%	9507
2022 Q3	$48K	Buy	+15,200	New	+$95.1K	﹤0.01%	11672
2022 Q2	–	Sell	-13,800	Closed	-$97K	–	14471
2022 Q1	$97K	Buy	+13,800	New	+$217K	﹤0.01%	12318

Citadel Advisors's ICVX Position: Q1 2024 in Review

Citadel Advisors sold out of Icosavax, Inc. Common Stock (ICVX) in Q1 2024, closing a stake of 275,779 shares — an estimated $4.35M sold.

Citadel Advisors first reported a position in ICVX in Q3 2021 and held it in 10 quarters. The position peaked at $35.2M in Q3 2021. 0 funds tracked by Wall St. Rank hold ICVX as of Q1 2024.

Citadel Advisors reported no remaining Icosavax, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Citadel Advisors sold 275,779 Icosavax, Inc. Common Stock shares in Q1 2024, an estimated $4.35M.
Citadel Advisors first reported a position in Icosavax, Inc. Common Stock in Q3 2021 and held it in 10 quarters.
Citadel Advisors's Icosavax, Inc. Common Stock position peaked at $35.2M in Q3 2021.
0 funds tracked by Wall St. Rank held Icosavax, Inc. Common Stock as of Q1 2024.

Based on Citadel Advisors's 13F filing for Q1 2024, filed 15 May 2024.